Zilucoplan for Myasthenia Gravis
(ziMyG+ Trial)

Recruiting in Palo Alto (17 mi)

+8 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: UCB Biopharma SRL

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants

Eligibility Criteria

This trial is for pediatric patients with generalized Myasthenia Gravis who are at least 2 years old and have completed the MG0014 study. They must be willing to get booster shots against meningococcal infections if needed.

Inclusion Criteria

I am 12 years old or older and can legally consent.

I am at least 2 years old and can legally consent.

I have finished the MG0014 study and, in my doctor's view, should keep taking zilucoplan.

+1 more

Participant Groups

The trial is testing Zilucoplan, a medication given by daily injection under the skin, over an additional year to see how safe and tolerable it is for long-term use in children with muscle weakness due to Myasthenia Gravis.

1Treatment groups

Experimental Treatment

Group I: Zilucoplan ArmExperimental Treatment1 Intervention

Study participants will receive Zilucoplan at a pre-defined dose based on their weight.

Zilucoplan is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Zilbrysq for: